CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at high risk of developing multiple my ...
Phase 2
Valencia, Spain and 13 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Phase 1, Phase 2
Valencia, Spain and 48 other locations
Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood s...
Phase 2
Valencia, Spain and 15 other locations
after Intensification therapy) and safety of Tec-Dara (Teclistamab+Daratumumab) and Tal-Dara (Talquetamab+Daratumumab) in de novo high-risk multiple...
Phase 2
Valencia, Spain and 9 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
Valencia, Spain and 126 other locations
provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding o ...
Phase 2
Valencia, Spain and 77 other locations
monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...
Phase 3
València, Spain and 218 other locations
escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple...
Phase 1
Valencia, Spain and 34 other locations
with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM).All eligible subjects must be previously treate...
Phase 1, Phase 2
Valencia, Spain and 53 other locations
combination with DEX for Relapsed Refractory Multiple Myeloma (RRMM), CC-220 in combination with DEX and BTZ, and CC-220 in combin ...
Phase 1, Phase 2
Valencia, Spain and 88 other locations
Clinical trials
Research sites
Resources
Legal